DEAN YOSHIMASA MAEDA

Summary

Publications

  1. doi request reprint Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model
    Dean Y Maeda
    Syntrix Biosystems, 215 Clay Street Northwest, Suite B5, Auburn, WA 98001, United States Electronic address
    Bioorg Med Chem Lett 25:2280-4. 2015
  2. ncbi request reprint Bivalent inhibitors of glutathione S-transferase: the effect of spacer length on isozyme selectivity
    Dean Y Maeda
    Syntrix Biosytems, Auburn, WA 98001, USA
    Bioorg Med Chem Lett 16:3780-3. 2006
  3. pmc Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism
    Dean Y Maeda
    Syntrix Biosystems, Inc, 215 Clay Street NW, Suite B 5, Auburn, WA 98001, USA
    J Pharmacol Exp Ther 332:145-52. 2010

Collaborators

Detail Information

Publications3

  1. doi request reprint Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model
    Dean Y Maeda
    Syntrix Biosystems, 215 Clay Street Northwest, Suite B5, Auburn, WA 98001, United States Electronic address
    Bioorg Med Chem Lett 25:2280-4. 2015
    ..Compound 6 (SX-576) is undergoing further investigation as a potential therapy for pulmonary inflammation...
  2. ncbi request reprint Bivalent inhibitors of glutathione S-transferase: the effect of spacer length on isozyme selectivity
    Dean Y Maeda
    Syntrix Biosytems, Auburn, WA 98001, USA
    Bioorg Med Chem Lett 16:3780-3. 2006
    ..7 vs 1022 nM, respectively) was achieved through the optimization of the spacer length between the ethacrynic acid ligand domains...
  3. pmc Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism
    Dean Y Maeda
    Syntrix Biosystems, Inc, 215 Clay Street NW, Suite B 5, Auburn, WA 98001, USA
    J Pharmacol Exp Ther 332:145-52. 2010
    ..Rapid inactivation by plasma esterases precluded use in vivo, but the mechanism elucidated provided insight for new nicotinamide pharmacophore classes with therapeutic potential...